Welcome to our dedicated page for TXXS news (Ticker: TXXS), a resource for investors and traders seeking the latest updates and insights on TXXS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TXXS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TXXS's position in the market.
21Shares (NASDAQ:TXXS) launched the 21Shares 2x Long Sui ETF (TXXS) on Nasdaq on December 4, 2025, offering the first US-listed 2x leveraged ETF tracking SUI through derivatives.
The fund charges a 1.89% fee and seeks 200% of SUI’s daily performance before fees; due to daily compounding, multi-day returns may differ significantly from 2x. Sui metrics cited include $10 billion in 30-day DEX volume (7th among chains) and $180 billion in stablecoin transfer volume for the fourth consecutive month. The launch follows 21Shares’ acquisition by FalconX.
